British pharmaceutical company GlaxoSmithKline announced on Thursday that it plans to sell all of its remaining shares in consumer care company Haleon.
The Zhitong Finance App learned that British pharmaceutical company GlaxoSmithKline (GSK.US) announced on Thursday that it plans to sell all of its remaining shares in consumer care company Haleon (HLN.US). According to reports, Haleon was divested from GlaxoSmithKline through a capital market transaction nearly two years ago.
According to the plan, as part of the sale of shares to institutional investors, GlaxoSmithKline will sell approximately 385 million shares of Haleon's common stock, equivalent to approximately 4.2% of Haleon's issued share capital.
Haleon is the parent company of household brands such as Sensodyne toothpaste and Panadol pain relievers. The company went public in July 2022, and GlaxoSmithKline held about 13% of the shares at the time.
The London-listed pharmaceutical giant has been reducing its Haleon shares and sold 810 million shares of common stock in a series of disposals in 2023 and 2024.
Recently, PFE.US (PFE.US) helped form Haleon by merging its consumer health business with GlaxoSmithKline's business and took steps to reduce its shareholding ratio from 32% to about 24% in March.